Topics in Transdermal Drug Delivery
Thu, May 29 12:00 pm – 2:00 pm
TO REGISTER
Email your name, title and company to register@massbio.org. Please include "5/29 FDD" in the subject line.
This event is free of charge and open to MBC Member companies and their employees only.
For more information on Membership, contact Lori Gold at lori.gold@massbio.org or 617-674-5149
Registration closes at approximately 3pm one day prior to a scheduled meeting. Unless a meeting is closed due to capacity you may attend as a walk-in registrant.
This meeting will be held at the MBC Offices, located on the ninth floor of One Cambridge Center, Cambridge, MA 02142.
Presenters and Abstracts
Needle-Free Powder Injection for Delivering Drugs and Vaccines
With the present safety issues clouding pulmonary delivery there is a revival in transdermal technologies. Previously, needle-free injection did not meet expectations because of the pain associated with the devices. Our needle-free powder injection device delivers biologicals and vaccines intradermally without pain while improving safety and efficacy. This needle-free technology allows to deliver drugs and vaccines in powder form at supersonic speed into the skin layers, with up to ten times the payload of any other system in development. In addition, the formulation in powder form may obviate the need for cold storage. Some preliminary preclinical case studies will be presented to illustrate the versatility of this technology for the transdermal delivery of biologicals and vaccines.
Speaker
Maurizio Cattaneo, Ph.D., Biovolutions Inc.
Iontophoretic-Based Drug Delivery for Transdermal Applications
In the area of transdermal drug delivery, Transport Pharmaceutical's ETS (Electrokinetic Transdermal/Transungual System) Drug/Device convergence technology combines novel medical electronics with proprietary formulations of drugs. SoloVir(TM) ETS, Phase 2 for herpes labialis, is a single 10-minute patient administered treatment which results in skin concentrations of the most commonly used anti-viral drug that are 100 times greater than seen with oral or topical applications. The focus of the talk will be on the development and clinical results of Solovir ETS as well as proof of concept experimental work for future applications involving iontophoretic delivery of large molecules and biologics.
Speaker
Shawn Davis, Ph.D.,Transport Pharmaceuticals Inc.
If you have ideas you would like to suggest or topics in drug delivery of biologics and speakers for upcoming meetings and future presentations, please feel free to contact either Lori Gold at the MBC at lori.gold@massbio.org or Michiel Lodder at lodder@octoplus-inc.com
PHONE: 617.674.5100
EMAIL: